The European Strategic Cluster Partnership on Personalised Healthcare, bioXclusters plus – which has joined together four leading European biotech clusters, Biocat (Catalonia), BioM (Bavaria), BioPmed (Piedmont) and Lyonbiopole (Auvergne Rhone-Alpes) – has organised a mission to Japan which will take place from 10th to 14th October 2016. This mission, which will visit Osaka and Yokohama, has been organised in collaboration with the EU Japan Centre.
The visiting delegation will be composed of representatives from the four metacluster partners and 26 SMEs from their respective regions:
2bind GmbH, 4SC AG, Ability Pharmaceuticals S.L., Apceth GmbH & Co. KG, Ascenion GmbH, Bioindustry Park Silvano Fumero SpA, Boeters &LieckCoriolis Pharma Research GmbH, CTIBiotech, CYTOO SA, FGK Clinical Research GmbH, Gams Wellness, genOway, Indicia Production, Iris Biotech GmbH, Klifovet AG, Laboratorios Rubió S.A, Laboratorios Salvat S.A., Leukocare AG, Leukos Biotech, Medigene AG, Mind the Byte S.L., Novotec, Theranexus, Thrombotargets Europe S.L., Zeclinics S.L.
An agenda dedicated to SMEs and networking
On 10th October, the company delegation will attend a one day training session dedicated to acquiring knowledge about the Japanese healthcare sector. This training is organised in cooperation with the EU-Japan Centre. On 11th October, it will participate in the “European Biotech & Pharma Partnering Conference” organised by bioXclusters plus with the support of the Osaka Bio Headquarters and the EU Japan Centre. It will be held at the Senri-Life Science Center in Osaka.
At this event, more than 150 participants from Japanese and European life science and healthcare companies will have the opportunity to network and meet in face-to-face meetings. Around 330 meetings are planned. This unique event is able to take place thanks to a growing collaboration between the bioXclusters plus’ partners and its Osaka counterparts.
During the last three days of the mission, the full delegation will attend the Bio Japan Conference in Yokohama, where European companies will have new opportunities to meet with other Japanese players. The Bio Japan convention is one of the largest events on biotechnologies in Asia and offers multiple business opportunities with around 800 companies that participate in the convention every year. Moreover, bioXclusters plus will introduce its initiative to Japan during the Bio Cluster summit at Bio Japan, organised by the Japan Bioindustry Association (JBA) on October 13th.
Developing long term strategic partnerships with Japan
Japan is one of the markets targeted by the bioXclusters plus’ alliance. Japan is the 2nd largest global market in healthcare after the US. It is characterised by high healthcare expenditure per capita, the use of advanced technology and a high level of R&D facilities which are supported by successive development plans by the government.
With an increasingly ageing population, biotechnology and medical technology solutions are playing a strategic role in the evolution of societal and economic challenges. They are advocated by the public authorities in Japan and the European Union in the coming years. Moreover, over the past few years, the pharma and medtech industry in Japan have been increasingly willing to foster collaborations with external players, in particular with those from Europe. These factors strongly reinforce the attractiveness of the market for European players, in particular SMEs.
For this reason, the priority of bioXclusters plus is to offer their SMEs the right tools to enter strategic markets of this type and showcase European competences through a unique delegation united under a single banner for maximum visibility.
In the following months, the alliance intends to build a “direct Gateway” to Japan for its European SMEs to reinforce their market access and to foster and fast-track business relationships.